Current in vitro approaches to assess nanoparticle interactions with lung cells

Nanomedicine

Volumn 11, Issue 18, 2016, Pages 2457-2469

  Fytianos, Kleanthis ^a   Drasler, Barbara ^a   Blank, Fabian ^b   Von Garnier, Christophe ^b   Seydoux, Emilie ^b   Rodriguez Lorenzo, Laura ^a   Petri Fink, Alke ^a   Rothen Rutishauser, Barbara ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

biomedical nanoparticles; immune modulation; in vitro approaches; lung immune cells; specific targeting

Indexed keywords

GOLD NANOPARTICLE; NANOCARRIER; NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CELL INTERACTION; COCULTURE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LUNG ALVEOLUS CELL; LYMPHOCYTE FUNCTION; MACROPHAGE; MONOCULTURE; NANOANALYSIS; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; DRUG EFFECTS; LUNG; NANOMEDICINE; RESPIRATORY SYSTEM;

DRUG DELIVERY SYSTEMS; HUMANS; LUNG; NANOMEDICINE; NANOPARTICLES; RESPIRATORY SYSTEM;

EID: 84984677302     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2016-0199     Document Type: Review

References (98)

1. Zhao L, Seth A, Wibowo N et al. Nanoparticle vaccines. Vaccine 32(3), 327-337 (2014).
2. Baetke SC, Lammers T, Kiessling F. Applications of nanoparticles for diagnosis and therapy of cancer. Brit. J. Radiol. 88, 1054 (2015).
3. Fenniri H. The Canadian regenerative medicine and nanomedicine enterprise (CARMENE). Int. J. Nanomed. 1(3), 225-227 (2006).
4. Oberdorster G, Stone V, Donaldson K. Toxicology of nanoparticles: a historical perspective. Nanotoxicology 1(1), 2-25 (2007).
5. Mills NL, Donaldson K, Hadoke PW et al. Adverse cardiovascular effects of air pollution. Nat. Clin. Pract. Card. 6(1), 36-44 (2009).
6. Oberdorster G. Pulmonary effects of inhaled ultrafne particles. Int. Arch. Occup. Environ. Health 74(1), 1-8 (2001).
7. Müller L, Lehmann AD, Johnston BD et al. Inhalation pathway as a promising portal of entry: what has to be considered in designing new nanomaterials for biomedical application? In: Handbook of Nan otoxico logy, Nanomedicine and Stem Cell Use in Toxicology. Sahu SC, Casciano DA (Eds). John Wiley & Sons, Ltd, Chichester, UK (2014).
8. Gehr P, Bachofen M, Weibel ER. Normal human lung-ultrastructure and morphometric estimation of diffusion capacity. Resp. Physiol. 32(2), 121-140 (1978).
9. Weibel ER. Morphometry of the human-lung-state of the art after 2 decades. B. Eur. Physiopath. Res. 15(5), 999-1013 (1979).
10. Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W Deposition of particles in the human respiratory-tract in the size range 0.005-15-Mu-M. J. Aerosol. Sci. 17(5), 811-825 (1986).
11. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug. Discov. 6(1), 67-74 (2007).
12. Schurch S, Gehr P, Hof VI, Geiser M, Green F. Surfactant displaces particles toward the epithelium in airways and alveoli. Resp. Physiol. 80(1), 17-32 (1990).
13. Gehr P, Schürch S, Berthiaume Y, Hof VI, Geiser M. Particle retention in airways by surfactant. J. Aerosol. Med. Pulm. Drug. Deliv. 3(1), 27-43 (2009).
14. Semmler-Behnke M, Takenaka S, Fertsch S et al. Effcient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent reentrainment onto airways epithelium. Environ. Health. Perspect. 115(5), 728-733 (2007).
15. Nemmar A, Hoet PHM, Vanquickenborne B et al. Passage of inhaled particles into the blood circulation in humans. Circulation 105(4), 411-414 (2002).
16. Kreyling WG, Hirn S, Moller W et al. Air-blood barrier translocation of tracheally instilled gold nanoparticles inversely depends on particle size. ACS Nano 8(1), 222-233 (2014).
17. Oberdorster G, Sharp Z, Atudorei V et al. Translocation of inhaled ultrafne particles to the brain. Inhal. Toxicol. 16(6-7), 437-445 (2004).
18. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharmaceut. 5(4), 505-515 (2008).
19. Hardy CL, Lemasurier JS, Belz GT et al. Inert 50-nm polystyrene nanoparticles that modify pulmonary dendritic cell function and inhibit allergic airway infammation. J. Immunol. 188(3), 1431-1441 (2012).
20. Kopf M, Schneider C, Nobs SP. The development and function of lung-resident macrophages and dendritic cells. Nat. Immunol. 16(1), 36-44 (2015).
21. Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL. Regulation of immunological homeostasis in the respiratory tract. Nat. Rev. Immunol. 8(2), 142-152 (2008).
22. Vermaelen K, Pauwels R. Pulmonary dendritic cells. Am. J. Resp. Crit. Care. 172(5), 530-551 (2005).
23. Upham JW, Stick SM, Moodley D. Lung cell biology. In: Pediatric Respiratory Medicine (2nd Edition). Taussig LM, Landau LI (Eds). Mosby Inc., an affliate of Elsevier Inc., PA, USA, 35-44 (2008).
24. Azarmi S, Roa WH, Loebenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliver. Rev. 60(8), 863-875 (2008).
25. Blank F, Stumbles PA, Seydoux E et al. Size-dependent uptake of particles by pulmonary antigen-presenting cell populations and traffcking to regional lymph nodes. Am. J. Resp. Cell. Mol. 49(1), 67-77 (2013).
26. Smith DM, Simon JK, Baker JR. Applications of nanotechnology for immunology. Nat. Rev. Immunol. 13 (8), 592-605 (2013).
27. Park YM, Lee SJ, Kim YS et al. Nanoparticle-based vaccine delivery for cancer immunotherapy. Immune Netw. 13 (5), 177-183 (2013).
28. Kononenko V, Narat M, Drobne D. Nanoparticle interaction with the immune system. Arh. Hig Rada. Toksiko. 66(2), 97-108 (2015).
29. Boraschi D, Duschl A. Nanoparticles and the Immune System: Safety and Effects (1st Edition). Academic Press, an imprint of Elsevier, Oxford, UK, 138 (2013).
30. Dobrovolskaia MA, Shurin M, Shvedova AA. Current understanding of interactions between nanoparticles and the immune system. Toxicol. Appl. Pharmacol. 299, 78-89 (2016).
31. Ilinskaya AN, Dobrovolskaia MA. Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future. Toxicol. Appl. Pharmacol. 299, 70-77 (2016).
32. Boraschi D, Costantino L, Italiani P. Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. Nanomedicine (Lond.) 7(1), 121-131 (2012).
33. Petri-Fink A, Rothen-Rutishauser B. Nanoparticles and cells: an interdisciplinary approach. Chimia 66(3), 104-109 (2012).
34. Mahon E, Salvati A, Bombelli FB, Lynch I, Dawson KA. Designing the nanoparticle-biomolecule interface for 'targeting and therapeutic delivery'. J. Control. Release 161(2), 164-174 (2012).
35. Moore TL, Rodriguez-Lorenzo L, Hirsch V et al. Nanoparticle colloidal stability in cell culture media and impact on cellular interactions. Chem. Soc. Rev. 44(17), 6287-6305 (2015).
36. Hirsch V, Kinnear C, Moniatte M, Rothen-Rutishauser B, Clift MJD, Fink A. Surface charge of polymer coated SPIONs Influences the serum protein adsorption, colloidal stability and subsequent cell interaction in vitro. Nanoscale 5(9), 3723-3732 (2013).
37. Tian FR, Clift MJD, Casey A et al. Investigating the role of shape on the biological impact of gold nanoparticles in vitro. Nanomedicine (Lond.) 10(17), 2643-2657 (2015).
38. Dreaden EC, Alkilany AM, Huang XH, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem. Soc. Rev. 41(7), 2740-2779 (2012).
39. Li JL, Wang L, Liu XY et al. In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles. Cancer Lett. 274(2), 319-326 (2009).
40. Papasani MR, Wang GK, Hill RA. Gold nanoparticles: the importance of physiological principles to devise strategies for targeted drug delivery. Nanomedicine 8(6), 804-814 (2012).
41. Keijzer C, Spiering R, Silva AL et al. PLGA nanoparticles enhance the expression of retinaldehyde dehydrogenase enzymes in dendritic cells and induce FoxP3(+) T-cells in vitro. J. Control. Release 168(1), 35-40 (2013).
42. Saluja SS, Hanlon DJ, Sharp FA et al. Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen. Int. J. Nanomed. 9, 5231-5246 (2014).
43. Rosalia RA, Cruz LJ, Van Duikeren S et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials 40, 88-97 (2015).
44. Cimalla P, Werner T, Winkler K et al. Imaging of nanoparticle-labeled stem cells using magnetomotive optical coherence tomography, laser speckle refectometry, and light microscopy. J. Biomed. Opt. 20(3), 036018 (2015).
45. Lee WH, Loo CY, Traini D, Young PM. Nano-and micro-based inhaled drug delivery systems for targeting alveolar macrophages. Expert Op in. Drug Del. 12(6), 1009-1026 (2015).
46. Seydoux E, Fytianos K, Von Garnier C, Rothen-Rutishauser B, Blank F. Targeting immune cells (Chapter 8d). In: The ISAM Textbook of Aerosol Medicine (1st Edition). Dhand R, Rothen-Rutishauser B, Hickey AJ (Eds). International Society of Aerosols in Medicine (ISAM)/Mary Ann Libert Publishing, Inc., NY, USA (2016).
47. Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv. Drug Deliver. Rev. 61(2), 140-157 (2009).
48. Ryan GM, Kaminskas LM, Kelly BD, Owen DJ, Mcintosh MP, Porter CJH. Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent. Mol. Pharmaceut. 10(8), 2986-2995 (2013).
49. Muttil P, Pulliam B, Garcia-Contreras L et al. Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses. AAPS J. 12(4), 699-707 (2010).
50. Thomas C, Rawat A, Hope-Weeks L, Ahsan F. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Mol. Pharmaceut. 8(2), 405-415 (2011).
51. Taratula O, Garbuzenko OB, Chen AM, Minko T Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target. 19(10), 900-914 (2011).
52. Carrillo-Conde B, Song EH, Chavez-Santoscoy A et al. Mannose-functionalized 'pathogen-like' polyanhydride nanoparticles target C-type lectin receptors on dendritic cells. Mol. Pharmaceut. 8(5), 1877-1886 (2011).
53. Stano A, Nembrini C, Swartz MA, Hubbell JA, Simeoni E. Nanoparticle size Influences the magnitude and quality of mucosal immune responses after intranasal immunization. Vaccine 30(52), 7541-7546 (2012).
54. Chiodo F, Marradi M, Park J et al. Galactofuranose-coated gold nanoparticles elicit a pro-infammatory response in human monocyte-derived dendritic cells and are recognized by DC-SIGN. ACS Chem. Biol. 9(2), 383-389 (2014).
55. Seydoux E, Rothen-Rutishauser B, Nita IM et al. Size-dependent accumulation of particles in lysosomes modulates dendritic cell function through impaired antigen degradation. Int. J. Nanomed. 9, 3885-3902 (2014).
56. Rodriguez-Lorenzo L, Fytianos K, Blank F, Von Garnier C, Rothen-Rutishauser B, Petri-Fink A. Fluorescence-encoded gold nanoparticles: library design and modulation of cellular uptake into dendritic cells. Small 10(7), 1341-1350 (2014).
57. Dekali S, Gameza C, Kortulewskic T, Blazya K, Ratb P, Lacroixa G. Assessment of an in vitro model of pulmonary barrier to study the translocation of nanoparticles. Toxicol. Rep. 1, 157-171 (2014).
58. Chaplin DD. Overview of the immune response. J. Allergy. Clin. Immun. 125(2), S3-S23 (2010).
59. Turvey SE, Broide DH. Innate immunity. J. Allergy Clin. Immun. 125(2), S24-S32 (2010).
60. Bonilla FA, Oettgen HC. Adaptive immunity. J. Allergy Clin. Immun. 125(2), S33-S40 (2010).
61. Balasubramanian SK, Poh KW, Ong CN, Kreyling WG, Ong W Y, Yu LE. The effect of primary particle size on biodistribution of inhaled gold nano-agglomerates. Biomaterials 34(22), 5439-5452 (2013).
62. Balhara J, Gounni AS. The alveolar macrophages in asthma: a double-edged sword. Mucosal. Immunol. 5(6), 605-609 (2012).
63. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8(12), 958-969 (2008).
64. Hamilton JA. Colony-stimulating factors in infammation and autoimmunity. Nat. Rev. Immunol. 8(7), 533-544 (2008).
65. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767-811 (2000).
66. Lehner M, Morhart P, Stilper A, Holter W. Functional characterization of monocyte-derived dendritic cells generated under serumfree culture conditions. Immunol. Lett. 99(2), 209-216 (2005).
67. Janeway CaJ, Travers P, Walport M, Shlomchik MJ. Immunobiology. The Immune System in Health and Disease (5th Edition). Garland Science, NY, USA (2001).
68. Bosco N, Kirberg J, Ceredig R, Agenes F. Peripheral T cells in the thymus: have they just lost their way or do they do something? Immunol. Cell. Biol. 87(1), 50-57 (2009).
69. Nakayamada S, Takahashi H, Kanno Y, O'shea JJ. Helper T cell diversity and plasticity. Curr. Opin. Immunol. 24(3), 297-302 (2012).
70. +) T cell stimulation by inhibition of antigen processing in dendritic cells. Nanotoxicology 5(4), 606-621 (2011).
71. Kato A, Hulse KE, Tan BK, Schleimer RP. B-lymphocyte lineage cells and the respiratory system. J. Allergy Clin. Immun. 131(4), 933-957 (2013).
72. Luo YH, Chang LW, Lin PP. Metal-based nanoparticles and the immune system: activation, infammation, and potential applications. Biomed. Res. Int. 143720, 1-12 (2015).
73. Chellat F, Merhi Y, Moreau A, Yahia L. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 26(35), 7260-7275 (2005).
74. Hirst SM, Peairs AD, Gogal R, Seal S, Reilly CM. Cerium oxide nanoparticles decrease infammation in J774 cells. FASEB J. 22, 758.2 (2008).
75. Bagalkot V, Badgeley MA, Kampfrath T, Deiuliis JA, Rajagopalan S, Maiseyeu A. Hybrid nanoparticles improve targeting to infammatory macrophages through phagocytic signals. J. Control. Release 217, 243-255 (2015).
76. Nicolete R, Dos Santos DF, Faccioli LH. The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro infammatory response. Int. Immunopharmacol. 11(10), 1557-1563 (2011).
77. Kagan VE, Kapralov AA, St Croix CM et al. Lung macrophages 'digest' carbon nanotubes. Using a superoxide/peroxynitrite oxidative pathway. ACS Nano 8 (6), 5610-5621 (2014).
78. Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG. Targeting nanoparticles to dendritic cells for immunotherapy. Method. Enzymol. 509, 143-163 (2012).
79. Le Guevel X, Palomares F, Torres MJ, Blanca M, Fernandez TD, Mayorga C. Nanoparticle size Influences the proliferative responses of lymphocyte subpopulations. RSC Adv. 5(104), 85305-85309 (2015).
80. Fytianos K, Rodriguez-Lorenzo L, Clift MJD et al. Uptake effciency of surface modifed gold nanoparticles does not correlate with functional changes and cytokine secretion in human dendritic cells in vitro. Nanomedicine 11(3), 633-644 (2015).
81. Temchura V V, Kozlova D, Sokolova V, Uberla K, Epple M. Targeting and activation of antigen-specifc B-cells by calcium phosphate nanoparticles loaded with protein antigen. Biomaterials 35(23), 6098-6105 (2014).
82. Lee CH, Syu SH, Chen YS et al. Gold nanoparticles regulate the blimp1/pax5 pathway and enhance antibody secretion in B-cells. Nanotechnology 25(12), 125103 (2014).
83. Shen CC, Wang CC, Liao MH, Jan TR. A single exposure to iron oxide nanoparticles attenuates antigen-specifc antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice. Int. J. Nanomed. 6, 1229-1235 (2011).
84. Meir R, Shamalov K, Betzer O et al. Nanomedicine for cancer immunotherapy: tracking cancer-specifc T-Cells in vivo with gold nanoparticles and CT imaging. ACS Nano 9(6), 6363-6372 (2015).
85. Liptrott NJ, Kendall E, Nieves DJ et al. Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'. Nanomedicine (Lond.). 9(16), 2467-2479 (2014).
86. Scott EA, Stano A, Gillard M, Maio-Liu AC, Swartz MA, Hubbell JA. Dendritic cell activation and T cell priming with adjuvant-and antigen-loaded oxidation-sensitive polymersomes. Biomaterials 33(26), 6211-6219 (2012).
87. Lehmann A, Brandenberger C, Blank F, Gehr P, Rothen-Rutishauser B. A 3D model of the human epithelial airway barrer. In: Methods in Bioengineering. Alternative Technologies to Animal Testing. Maguire T, Novik E (Eds). Artech House Boston, London, UK, 239-260 (2010).
88. Rothen-Rutishauser BM, Kiama SG, Gehr P. A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. Am. J. Resp. Cell. Mol. 32(4), 281-289 (2005).
89. Blank F, Rothen-Rutishauser BM, Schurch S, Gehr P. An optimized in vitro model of the respiratory tract wall to study particle cell interactions. J. Aerosol. Med. 19(3), 392-405 (2006).
90. Rothen-Rutishauser B, Lehmann AD, Clift MJD, Blank F, Gehr P. Laser scanning microscopy combined with image restoration to analyse a 3D model of the human epithelial airway barrier. Swiss. Med. Wkly. 140, 3-9 (2010).
91. Lenz AG, Karg E, Lentner B et al. A dose-controlled system for air-liquid interface cell exposure and application to zinc oxide nanoparticles. Part. Fibre. Toxicol. 6, 32 (2009).
92. Giese C, Marx U. Human immunity in vitro-solving immunogenicity and more. Adv. Drug. Deliver. Rev. 69103-122 (2014).
93. Villiers CL, Freitas H, Couderc R, Villiers MB, Marche PN. Analysis of the toxicity of gold nano particles on the immune system: effect on dendritic cell functions. J. Nanopart. Res. 12(1), 55-60 (2010).
94. Braakhuis HM, Park MVDZ, Gosens I, De Jong WH, Cassee FR. Physicochemical characteristics of nanomaterials that affect pulmonary infammation. Part. Fibre Toxicol. 11, 18 (2014).
95. + T cell proliferation Nanomedicine: NBM 12(7), 1815-1826 (2016).
96. Teeguarden JG, Mikheev VB, Minard KR et al. Comparative iron oxide nanoparticle cellular dosimetry and response in mice by the inhalation and liquid cell culture exposure routes. Part. Fibre Toxicol. 11, 46 (2014).
97. Fadeel B. Clear and present danger? Engineered nanoparticles and the immune system. Swiss. Med. Wkly 142, w13609 (2012).
98. Silva JM, Videira M, Gaspar R, Preat V, Florindo HF. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J. Control. Release 168(2), 179-199 (2013).